Scarica l'app Stockscreener
11.62
3.17%
-0.38
Dopo l'orario di chiusura:
11.62
Precedente Chiudi:
$12.00
Aprire:
$11.88
Volume 24 ore:
2.93M
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.35B
Reddito:
$52.86M
Utile/perdita netta:
$-480.19M
Rapporto P/E:
-2.4777
EPS:
-4.6899
Flusso di cassa netto:
$-421.82M
1 W Prestazione:
+4.78%
1M Prestazione:
+1.66%
6M Prestazione:
+7.00%
1 anno Prestazione:
+22.19%
Intervallo 1D:
$11.21
$11.95
Intervallo di 1 settimana:
$11.21
$12.54
Portata 52W:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.62 | 1.39B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Will Intellia Therapeutics Inc. stock reach Wall Street targets2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
Should you avoid Intellia Therapeutics Inc. stock right nowJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Sahm
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - AOL.com
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - The Motley Fool
Intellia Therapeutics (NTLA) Awards Inducement Grants to New Emp - GuruFocus
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
Best Gene-Editing Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock Trajectory In 2026 (NTLA) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossNTLA - Nasdaq
Intellia Therapeutics Receives Key Regulatory Clearance for Clinical Trial - AD HOC NEWS
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia Therapeutics (NTLA) Price Target Increased by 35.10% to 23.94 - Nasdaq
The Technical Signals Behind (NTLA) That Institutions Follow - Stock Traders Daily
Intellia Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily
FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang - Sahm
FDA Lifts Hold On Intellia Trial Refocusing Attention On Valuation Upside - Yahoo Finance
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Yahoo Finance
FDA Lifts MAGNITUDE-2 Hold Refocusing Intellia’s ATTR Value Story - Sahm
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal - Finviz
Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
The week in pharma: action, reaction and insight – week to January 30, 2026 - The Pharma Letter
Travel Stocks: Is Intellia Therapeutics Inc a top pick in the sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial - Sahm
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial - Sahm
FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials - NeurologyLive
Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views - Benzinga
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6%Time to Sell? - MarketBeat
NTLA Stock Rating Maintained and Price Target Raised by HC Wainw - GuruFocus
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Y Intercept Hong Kong Ltd Makes New $2.37 Million Investment in Intellia Therapeutics, Inc. $NTLA - MarketBeat
H.C. Wainwright raises Intellia Therapeutics stock price target on clinical hold lift - Investing.com Canada
Brokers Offer Predictions for NTLA FY2030 Earnings - MarketBeat
Intellia Gets Nex-z Phase III Study Boost After FDA Lifts Clinical Hold - Citeline News & Insights
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance
Intellia Therapeutics - The Pharma Letter
FDA Clears MAGNITUDE-2 Hold Leaving Intellia Cardiomyopathy Questions Open - Yahoo Finance
Intellia Therapeutics to resume dosing of gene therapy in Phase III trial - Clinical Trials Arena
Intellia gets FDA nod to resume one gene therapy trial after safety pause - ET Pharma
Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - MSN
Intellia’s nex-z moves ahead, but only for ATTR-PN for now - BioWorld MedTech
FDA Lifts Hold on Intellia's Nexiguran Ziclumeran Program (NTLA) - GuruFocus
Can Intellia Therapeutics Inc. sustain its profitabilityTrend Reversal & Risk Adjusted Buy and Sell Alerts - mfd.ru
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):